Krilogy Financial LLC Grows Position in Danaher Co. (NYSE:DHR)

Krilogy Financial LLC raised its position in Danaher Co. (NYSE:DHRGet Rating) by 90.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,567 shares of the conglomerate’s stock after purchasing an additional 1,216 shares during the quarter. Krilogy Financial LLC’s holdings in Danaher were worth $651,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. US Asset Management LLC raised its holdings in shares of Danaher by 0.6% during the 1st quarter. US Asset Management LLC now owns 5,774 shares of the conglomerate’s stock valued at $1,694,000 after buying an additional 37 shares during the period. Mairs & Power Inc. grew its stake in Danaher by 4.1% during the 4th quarter. Mairs & Power Inc. now owns 959 shares of the conglomerate’s stock valued at $316,000 after purchasing an additional 38 shares in the last quarter. Mutual Advisors LLC grew its stake in Danaher by 0.7% during the 4th quarter. Mutual Advisors LLC now owns 5,792 shares of the conglomerate’s stock valued at $1,906,000 after purchasing an additional 40 shares in the last quarter. Encompass Wealth Advisors LLC grew its stake in Danaher by 1.9% during the 1st quarter. Encompass Wealth Advisors LLC now owns 2,292 shares of the conglomerate’s stock valued at $672,000 after purchasing an additional 42 shares in the last quarter. Finally, Howe & Rusling Inc. grew its stake in Danaher by 48.8% during the 1st quarter. Howe & Rusling Inc. now owns 128 shares of the conglomerate’s stock valued at $38,000 after purchasing an additional 42 shares in the last quarter. 77.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Danaher

In related news, CEO Rainer Blair sold 25,000 shares of Danaher stock in a transaction on Monday, August 15th. The stock was sold at an average price of $300.00, for a total value of $7,500,000.00. Following the transaction, the chief executive officer now directly owns 79,739 shares in the company, valued at approximately $23,921,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Danaher news, EVP Joakim Weidemanis sold 12,000 shares of the business’s stock in a transaction dated Monday, July 25th. The stock was sold at an average price of $271.13, for a total value of $3,253,560.00. Following the transaction, the executive vice president now owns 74,398 shares in the company, valued at $20,171,529.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rainer Blair sold 25,000 shares of the business’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $300.00, for a total value of $7,500,000.00. Following the completion of the transaction, the chief executive officer now owns 79,739 shares in the company, valued at approximately $23,921,700. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,906 shares of company stock valued at $11,823,179. Corporate insiders own 11.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Cowen lowered their price objective on Danaher to $340.00 in a research note on Friday, July 22nd. Evercore ISI lowered their price objective on Danaher from $320.00 to $280.00 and set an “outperform” rating for the company in a research note on Tuesday, July 5th. Robert W. Baird raised their price objective on Danaher from $319.00 to $325.00 in a research note on Friday, July 22nd. Royal Bank of Canada lifted their target price on Danaher from $317.00 to $318.00 and gave the stock an “outperform” rating in a research report on Friday, September 16th. Finally, Credit Suisse Group began coverage on Danaher in a research report on Wednesday, August 24th. They issued an “outperform” rating and a $340.00 target price for the company. One investment analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $321.75.

Danaher Stock Down 0.8 %

Shares of Danaher stock opened at $266.43 on Friday. The business’s fifty day moving average price is $280.99 and its two-hundred day moving average price is $269.91. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.75 and a quick ratio of 1.32. The company has a market capitalization of $193.81 billion, a P/E ratio of 31.38, a PEG ratio of 1.29 and a beta of 0.88. Danaher Co. has a 1-year low of $233.71 and a 1-year high of $331.68.

Danaher (NYSE:DHRGet Rating) last posted its quarterly earnings data on Thursday, July 21st. The conglomerate reported $2.76 EPS for the quarter, topping analysts’ consensus estimates of $2.35 by $0.41. Danaher had a return on equity of 18.57% and a net margin of 20.61%. The company had revenue of $7.75 billion for the quarter, compared to the consensus estimate of $7.29 billion. During the same quarter in the previous year, the business earned $2.46 EPS. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. As a group, research analysts forecast that Danaher Co. will post 10.4 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Stockholders of record on Friday, September 30th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.38%. The ex-dividend date is Thursday, September 29th. Danaher’s dividend payout ratio is presently 11.78%.

About Danaher

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

Recommended Stories

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.